丹麦登记队列研究:苯二氮䓬类药物的长期使用与剂量升级风险
结果显示,在950,767例首次使用者中,15%长期使用超过1年、3%超过7年;仅7%(N=3,545)升级至超推荐剂量,精神科共病(尤其物质使用障碍)与长期使用和剂量升级风险升高相关。
要点
- 首次BZRA使用者中15%长期使用超1年、3%超7年,Z-drug起始者比例最高(17.8%和4%)。
- 仅7%(N=3,545)BZRA使用者剂量升级至超推荐水平,持续使用≥3年者中位剂量相对稳定。
- 精神科共病尤其是物质使用障碍与长期使用及剂量升级风险升高相关。
核心结论
- 在现行监管下,BZRA使用者中连续使用和剂量升级至超推荐水平的比例有限,不支持BZRA使用常导致长期使用或剂量升级的观点。
主要发现
- 共识别950,767例BZRA首次使用者,其中15%长期使用超过1年,3%长期使用超过7年;Z-drug起始者长期使用比例最高(17.8%和4%)。
- 在持续使用至少3年的5%BZRA使用者中,中位剂量保持相对稳定,未见剂量升级迹象。
- 7%(N=3,545)的BZRA使用者剂量升级至超过推荐水平。
- 精神科共病,尤其是物质使用障碍,与长期使用和剂量升级风险升高相关。
关键数值与推荐
- 长期使用定义为使用超过1年或超过7年;剂量升级定义为剂量增加至超过推荐水平。
临床怎么用
- 临床处方BZRA时可参考该人群数据:多数使用者未发展为长期使用或超推荐剂量升级,但需关注精神科共病尤其是物质使用障碍患者的高风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors investigated the frequency and determinants of long-term use and risk of dose escalation of benzodiazepines and benzodiazepine-related drugs (benzodiazepine receptor agonists, or BZRAs). METHODS: All adults ages 20-80 years living in Denmark on January 1, 2000 (N=4,297,045) were followed for redeemed prescriptions of BZRAs in the Danish National Prescription Registry from January 1, 2000, to December 31, 2020. For each drug class, we calculated long-term use for more than 1 or 7 years, and dose escalation measured as increase in dose to a level above the recommended level. Associations were examined using logistic regression. RESULTS: The authors identified 950,767 incident BZRA users, of whom 15% and 3% became long-term users for more than 1 or 7 years, respectively. These percentages were highest for individuals who initiated Z-drugs (17.8% and 4%). Among the 5% of BZRA users who had at least 3 years of continuous use, there was no indication of dose escalation, as the median dose remained relatively stable. However, 7% (N=3,545) of BZRA users escalated to doses above the recommended level. Psychiatric comorbidity, especially substance use disorder, was associated with higher risk of long-term use and dose escalation. CONCLUSIONS: A limited portion of the population that received BZRA prescriptions were classified as continuous users, and only a small proportion of this group escalated to doses higher than those recommended in clinical guidelines. Thus, this study does not, under the current regulations, support the belief that BZRA use frequently results in long-term use or dose escalation.
引用
- Rosenqvist TW, Wium-Andersen MK, Wium-Andersen IK, et al. Long-Term Use of Benzodiazepines and Benzodiazepine-Related Drugs: A Register-Based Danish Cohort Study on Determinants and Risk of Dose Escalation. Am J Psychiatry. 2023. PMID: 37727098. doi:10.1176/appi.ajp.20230075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。